Table 1

Expression status of IGFBP-3 according to the clinicopathological features of patients with stage I NSCLC

Loss of expression (42/74)Without loss of expression (32/74)TotalP
Age, yr, mean± SD63.3± 9.9363.1± 9.0263.2± 9.480.951
Sex, n (%)0.796
 Male30 (40.5)24 (32.4)54
 Female12 (16.2)8 (10.8)20
Pathology, n (%)0.083
 Adenocarcinoma20 (27.0)18 (24.3)
 Squamous carcinoma16 (21.6)14 (18.9)
 Others6 (8.1)0 (0.0)
Histological grade, n (%)0.186
 Well differentiated2 (2.7)0 (0.0)2
 Moderately differentiated14 (18.9)13 (17.5)27
 Poorly differentiated18 (24.3)11 (14.9)29
 Undifferentiated/Anaplastic3 (4.1)0 (0.0)3
 Unclassified5 (6.8)8 (10.8)13
Smoking status, n (%)0.43
 Current; pack-year37 (50.0); 62.2± 39.5330 (40.5); 69.6± 36.0467 (90.5); 62.7± 39.410.32
 Nonsmoker3 (4.1)1 (1.4)4 (5.4)
 Unknown2 (2.7)1 (1.4)3 (4.1)
5-year survival probability (%)
 Overall51.371.00.0876
 Disease specific64.685.70.0193
 Disease free54.471.40.1025